In this alert we highlight the following issues concerning GMOs in South Africa:
On this page you will find all of ACB’s publications. To the right are the search categories that will help you navigate around the ACB’s extensive work.
In 2015–2016 Dow AgroSciences Southern Africa (Pty) Ltd performed field trials on maize tolerant to 2,4-D (event DAS-87078-9) and stacked varieties carrying not only 2,4-D tolerance, but also glyphosate tolerance and/or Bt insectidal toxins. The trials are on going in 2017.
Press Release from the African Centre for Biodiversity (ACB), Trust for Community Outreach and Education (TCOE) and the Commercial & the Stevedoring, Agricultural and Allied Workers Union (CSAAWU) Thursday, 25 May 2017 The African Centre for Biodiversity (ACB) has published a briefing paper today titled, ‘South Africa and 2,4 D GM maize: Bio
This briefing deals with the three mega mergers taking place in the agriculture sector as Dow Chemical and DuPont are set to merge, China National Chemical Corporation (ChemChina) is to acquire Syngenta and Bayer is to acquire Monsanto.
This submission is made by the ABC because of serious public interest concerns about the proposed merger between Bayer and Monsanto. This merger is occurring in the context of other related mergers in agricultural input supply, between ChemChina-Syngenta and Dow-Du Pont.
During May 2012, the South African GMO authorities1 approved Dow Chemical's highly controversial GM maize variety, DAS-40278-9 for import into South Africa for direct use as food, feed and processing.
Stacked GMOs are those containing more than one gene genetically engineered into a crop plant. A controversial stacked GMO, Smarstax containing 8 such genetically engineered genes, was commercially approved in the US, Canada, Japan and South Korea during 2009.